ArticleArchivos de bronconeumologia2022
The Impact of COVID-19 in Cystic Fibrosis.
Article in Archivos de bronconeumologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Comparative clinical and epidemiological characteristics of influenza and COVID-19 in hospitalized pediatric patients in Romania during and after the SARS-CoV-2 pandemic.Journal of medicine and life · 2026Observational
- Impact of the COVID-19 pandemic on sex-related disparities in cystic fibrosis healthcare utilization and outcomes: A population study.PloS one · 2026Article
- Article
- Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- Influenza, SARS-CoV-2, and Their Impact on Chronic Lung Diseases and Fibrosis: Exploring Therapeutic Options.The American journal of pathology · 2024Review
- The cost of simplifying treatments for cystic fibrosis: Implications of the SIMPLIFY trial.Journal of managed care & specialty pharmacy · 2024Article
- Occurrence of COVID-19 in cystic fibrosis patients: a review.Frontiers in microbiology · 2024Review
- Impact of COVID-19 pandemic on health care system, work, and mental well-being of people with cystic fibrosis.Irish journal of medical science · 2023Article
- Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis?Vaccines · 2023Article
- SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far.Life (Basel, Switzerland) · 2022Review
- Real-life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients.Pharmacology research & perspectives · 2022Observational
- Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases.Archivos de bronconeumologia · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.